Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [11C]PHNO PET - Rabiner, Eugenii A.; Uz, Tolga; Mansur, Ayla; Brown, Terry; Chen, Grace; Wu, Jingtao; Atienza, Joy; Schwarz, Adam J.; Yin, Wei; Lewis, Yvonne; Searle, Graham E.; Dennison, Jeremy M. T. J.; et al. (Neuropsychopharmacology (New York, N.Y.), 2022)
Keywords: Agonists; Amphetamine - pharmacology; Amphetamines; Biomarkers; Biomarkers - metabolism; Brain; Central nervous system; Cognitive ability; Dextroamphetamine - pharmacology; Dopamine; Dopamine - metabolism; Dopamine Agonists - metabolism; Dopamine Agonists - pharmacology; Dopamine receptors; Drug delivery; Drug development; Drug dosages; G protein-coupled receptors; Humans; Mental disorders; Neostriatum; Nerve Tissue Proteins - metabolism; Pharmacodynamics; Positron emission tomography; Positron-Emission Tomography - methods; Putamen; Receptors, Dopamine D3 - metabolism; Receptors, G-Protein-Coupled - metabolism; Schizophrenia